ANTI-DOPING-2022: Anti-doping Activities
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Office of National Drug Control Policy notices from 2022.
Office of National Drug Control Policy offered grants of up to $15.0 million (at least $15.0 million) to the applicants described in the notice. It expected to make one award. Applications closed on April 29, 2022.
From the official notice on Grants.gov, last changed March 30, 2022. Checked November 7, 2026.
- Award ceiling$15.0 million
- Award floor$15.0 million
- Expected awards1
- Cost sharingNot required
- Funding typeGrant
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| ADA-ADA-23-001 | March 20, 2023 | Closed April 28, 2023 | Closed |
| ANTI-DOPING-2021 | March 22, 2021 | Closed April 22, 2021 | Closed |
Key dates
| Posted | March 31, 2022 |
|---|---|
| Deadline | April 29, 2022 |
| Archived by Grants.gov | May 29, 2022 |
Who can apply
This opportunity was open to the applicants described in the notice.
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Applicant must be able to serve as the United States representatives responsible for coordination with other anti-doping organizations coordinating amateur athletic competitions recognized by the United States Olympic and Paralympic Committee. Applicant must be recognized by the United States Olympic and Paralympic Committee as the official anti-doping agency for the United States
Is this a realistic fit?
- Past Anti-Doping Activities awards averaged $14.4 million; this notice allows up to $15.0 million per award.
- Most of the program's money (100% over five years) went to nonprofits.
- No cost sharing or match is required.
What the grant funds
The United States Anti-Doping Agency Reauthorization Act, 21 U.S.C. §§ 2001 et seq. provides that the United States Anti-Doping Agency shall– 1) Serve as the independent anti-doping organization for the amateur athletic competitions recognized by the United States Olympic & Paralympic Committee and be recognized worldwide as the independent national anti-doping organization for the United States; 2) Ensure that athletes participating in amateur athletic activities recognized by the United States Olympic & Paralympic Committee are prevented from using performance-enhancing drugs or other prohibited performance-enhancing methods adopted by the Agency; 3) Implement anti-doping education, research, testing, and adjudication programs to prevent United States Amateur Athletes participating in any activity recognized by the United States Olympic & Paralympic Committee from using performance-enhancing drugs or prohibited performance-enhancing methods adopted by the Agency; 4) Promote a positive youth experience by using a portion of the funding of the United States Anti-Doping Agency to provide educational materials on sportsmanship, character building, and healthy performance for the athletes, parents, and coaches who participate in youth sports; 5) Certify in advance any testing conducted by international organizations under the World Anti-Doping Code for international amateur athletes and athletic competitions occurring within the jurisdiction of the United States; 6) Serve as the United States representative responsible for coordination with other national anti-doping organizations coordinating amateur athletic competitions recognized by the United States Olympic & Paralympic Committee to ensure the integrity of athletic competition, the health of the athletes, and the prevention of use by United States amateur athletes of performance-enhancing drugs or prohibited performance-enhancing methods adopted by the Agency. 21 U.S.C. § 2001(b)(1) – (4). The grantee is required to provide continued support of anti-doping efforts to educate athletes on the dangers of drug use and eliminate doping in amateur athletic competitions recognized by the United States Olympic & Paralympic Committee.
Who has won Anti-Doping Activities grants before
From fiscal 2021 to 2025, Anti-Doping Activities (95.004) awarded $72.3 million across 5 grant awards, an average of $14.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| United States Anti-Doping Agency | Colorado | 5 | $72.3 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is ANTI-DOPING-2022 still open?
No. It closed on April 29, 2022.
Who can apply for Anti-doping Activities?
Office of National Drug Control Policy accepted applications from the applicants described in the notice. The notice adds further conditions, so read its eligibility section.
What is the deadline for Anti-doping Activities?
Closed April 29, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $15.0 million each.
Who has won Anti-Doping Activities grants before?
The largest recipients over five fiscal years were United States Anti-Doping Agency. The program made 5 awards worth $72.3 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)